BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 30562637)

  • 1. Methylation of gene CHFR promoter in acute leukemia cells.
    Gong H; Liu W; Zhou J; Xu H
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
    Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHFR: a key checkpoint component implicated in a wide range of cancers.
    Sanbhnani S; Yeong FM
    Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear localization of Chfr is crucial for its checkpoint function.
    Kwon YE; Kim YS; Oh YM; Seol JH
    Mol Cells; 2009 Mar; 27(3):359-63. PubMed ID: 19326084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of poly(ADP-ribose) recognition by the multizinc binding domain of checkpoint with forkhead-associated and RING Domains (CHFR).
    Oberoi J; Richards MW; Crumpler S; Brown N; Blagg J; Bayliss R
    J Biol Chem; 2010 Dec; 285(50):39348-58. PubMed ID: 20880844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
    Sanoff HK; Renfro LA; Poonnen P; Ambadwar P; Sargent DJ; Goldberg RM; McLeod H
    PLoS One; 2014; 9(4):e94727. PubMed ID: 24727911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on sequencing third-line therapies for metastatic colorectal cancer.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):10-14. PubMed ID: 38805299
    [No Abstract]   [Full Text] [Related]  

  • 8. How best to extend overall survival in metastatic colorectal cancer: Q&A.
    Bekaii-Saab TS; Barzi A; Cusnir M
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):16-17. PubMed ID: 38805301
    [No Abstract]   [Full Text] [Related]  

  • 9. A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
    Kearney MR; Chen EY; Vaccaro GM; Strother J; Burt A; Todd K; Donovan J; Kampa-Schittenhelm KM; Lopez CD
    Anticancer Res; 2019 Jan; 39(1):245-252. PubMed ID: 30591465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis.
    He F; Ye B; Wu X; Pan J; Wang J; Wang X
    BMC Gastroenterol; 2023 Apr; 23(1):114. PubMed ID: 37024798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review.
    Ghadiri Moghaddam F; Farajnia S; Karbalaei-Mahdi M; Monir L
    Mol Biol Rep; 2022 Oct; 49(10):10013-10022. PubMed ID: 35727475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
    González-Borja I; Alors-Pérez E; Amat I; Alonso L; Viyuela-García C; Goñi S; Reyes JC; Ceballos-Chávez M; Hernández-García I; Sánchez-Frías ME; Santamaría E; Razquin S; Arjona-Sánchez Á; Arrazubi V; Pérez-Sanz J; Vera R; Fernández-Irigoyen J; Castaño JP; Viúdez A
    Front Med (Lausanne); 2021; 8():720128. PubMed ID: 34869418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma.
    Tomicic MT; Dawood M; Efferth T
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative omics analysis reveals effective stratification and potential prognosis markers of pan-gastrointestinal cancers.
    Jiangzhou H; Zhang H; Sun R; Fahira A; Wang K; Li Z; Shi Y; Wang Z
    iScience; 2021 Aug; 24(8):102824. PubMed ID: 34381964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation-Based Therapies for Colorectal Cancer.
    Cervena K; Siskova A; Buchler T; Vodicka P; Vymetalkova V
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
    Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
    Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.